Dose–response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT)

INTRODUCTION: An extrafine formulation of the long-acting muscarinic antagonist, glycopyrronium bromide (GB), has been developed for delivery via the NEXThaler dry powder inhaler (DPI). This study assessed the bronchodilator efficacy and safety of different doses of this formulation in patients with...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Int J Chron Obstruct Pulmon Dis
Asıl Yazarlar: Beeh, Kai M, Emirova, Aida, Prunier, Hélène, Santoro, Debora, Nandeuil, Marie Anna
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2018
Konular:
Clinical Trial Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5973313/
https://ncbi.nlm.nih.gov/pubmed/29872288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S168493
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller